Status:
COMPLETED
Carotid Artery Stenting With Cilostazol Addition for Restenosis
Lead Sponsor:
Kobe City General Hospital
Collaborating Sponsors:
Chiba University
Nagoya University
Conditions:
In-stent Restenosis After Carotid Artery Stenting
Eligibility:
All Genders
45-80 years
Phase:
NA
Brief Summary
CAS-CARE study was conducted to evaluate the inhibitory effect of cilostazol, compared to that of other antiplatelet drugs, on in-stent restenosis following carotid artery stenting (CAS) in patients s...
Detailed Description
Restenosis after carotid artery stenting (CAS) is a critical issue. Cilostazol can reduce restenosis after interventions in coronary or femoropopliteal arteries. The investigators confirmed and publis...
Eligibility Criteria
Inclusion
- 50% or more symptomatic carotid artery stenosis or 80% or more asymptomatic carotid artery stenosis
- scheduled for carotid artery stenting within 30 days
- 45 or more years-old and less than 80 years old
- antiplatelet agents can be administratered orally
- follow-up is anticipated possible for 2 years after CAS
- self-supporoted in daily activities (modified Rankin Scale 2 or less)
- patients who have given informed consent to participation in the study
Exclusion
- received endovascular interevention
- scheduled for bilateral carotid intervention
- aortitis or cvasculitis
- congessive heart failure
- ischemic stroke within 48 hours
- hemorrhagic stroke within 90 days
- renal failure
Key Trial Info
Start Date :
December 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2019
Estimated Enrollment :
707 Patients enrolled
Trial Details
Trial ID
NCT01261234
Start Date
December 1 2010
End Date
September 1 2019
Last Update
October 16 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Kobe City Medical Center General Hospital
Kobe, Hyōgo, Japan, 650-0046